3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)
Book tickets
3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)
Overview:
The iPAM® is a congregation for delegates to attend and share ideas of good medical practice and latest evidence-based interventions in the field of psychiatry and addiction.
The 1st iPAM ® was delivered as a virtual conference during Covid 19 pandemic on 14th and 15th November 2020 from Dubai, UAE. We had hundreds of registrations from across five continents. Approximately a hundred questions were asked and answered during the two-day sessions and on an average 90% of the attendees rated the content, session and faculty from very good to excellent.
The 2nd iPAM ® was delivered on the 15th October 2021 in Dubai, UAE as a hybrid event and our speakers presented their expert views on the current evidence around various themes related to mental health, addiction, psychological interventions, interface of mental health with physical health and emerging trends in psychiatry. It was a resounding success.
The 3rd iPAM will be successfully organised on the 1st of October 2025 in London, UK. We have excellent speakers delivering their expert views over various topics. Our faculty will be delivering their sessions from the UAE, United Kingdom, United States of America and from other GCC countries.
Who Will Attend:
Each year iPAM ® will develop new and upcoming themes which will be deemed necessary and useful for the attending delegates.
- Doctors- Psychiatrists, GPs, Hepatologists etc.
- Psychologists
- Any HCP working in the field of psychiatry and addiction.
- Nurses
- Social workers
Sponsors & Partners
Conference Speakers
David Nutt
FMedSci
Psychiatrist and Prof of Neuropsychopharmacology
Imperial College London
Read biography
Dr Baxi
Sinha
Consultant Psychiatrist & Lead, Ketamine Service for TRD Deputy Medical Director (IR)
TEWV NHS Foundation Trust
Read biography
Dr Hasanen
Al-Taiar
Consultant Forensic Psychiatrist Forensic TPD. Medical Member HM Tribunal Service
The Oxford Clinic, Littlemore Mental Health Centre
Read biography
Dr Khurram
Sadiq
Medical Lead Adult ADHD/ Clinical Care Lead Adult ADHD SE London ICB/ Consultant Neurodevelopmental Psychiatrist
Oxleas NHS Foundation Trust
Read biography
Prof Mohammed
Al-Uzri
Presidential Lead for Global Mental Health
The Royal College of Psychiatrists
Read biography
Professor Cathy
Montgomery
Professor of Psychopharmacology & Health Inequalities; Head of Institute for Health Research
Liverpool John Moores University
Read biography
Professor Subodh
Dave
Dean for RCPsych | Consultant Liaison Psychiatrist & Deputy Director of Undergraduate Medical Education, Derbyshire Healthcare Foundation Trust
Professor of Psychiatry, University of Bolton | Board Member, Centre for Research Equity, University of Oxford
Read biographyThe programme
Registration
Registration
Introducing the 3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)
Introducing the 3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)
Chair: Dr Khansa Nabil (Confirmed)
Ketamine infusion for treatment resistant depressive disorder (Confirmed)
This presentation captures real-world experience from the NHS in implementing Ketamine treatment for Treatment-Resistant Depression. Sharing treatment protocols, it highlights how a motivated team, working within the constraints of limited resources, established and sustains an innovative service that is making a positive difference in clinical outcomes.
Ketamine Addiction - Should we be concerned? (Confirmed)
The presentation will cover the prevalence and harms of ketamine addiction. It will also cover what Via is doing in the community and at the Passmores House detox and rehabilitation unit to support those with a Ketamine addiction.
Ketamine Assisted Psychotherapy (Confirmed)
The talk will introduce the audience to ketamine assisted psychotherapy with a focus on its use in alcohol and substance use disorders.
Q&A
Q&A
Tea Break and Networking
Tea Break and Networking
Chair Morning Reflections (Confirmed)
AuDHD- A New Paradigm in Neurodiversity….
There is new evidence to suggest that the co-occurrence of autism and ADHD can be as much as 50-70%. In the colloquial community, this co-occurrence is termed AuDHD. Is this a new term or a New Diagnosis on the horizon, or an extension of the spectrum … The presentation of co-occurring Autism and ADHD is different from that of Pure Autism or Pure ADHD, and are there different types of AuDHD … this will all be covered in this session…
Does addiction present differently in people with Neurodiversity? (Confirmed)
As clinicians, we are increasingly recognising and developing competencies in identifying and managing neurodiversity-related conditions, particularly adult ADHD and autism. Individuals with a dual diagnosis—neurodiversity co-occurring with other mental health conditions such as addictions—pose a distinct set of clinical challenges. Their addictive behaviours, whether substance-related or behavioural (e.g. problem gambling, gaming, internet use, social media, or smartphone overuse), may present atypically and often prove more resistant to conventional treatment approaches.
This presentation explores the complexities of such dual diagnosis cases, with a focus on both substance misuse and the growing recognition of behavioural addictions. It underscores the need for mental health services to adapt and provide responsive, neurodiversity-informed care pathways.
Forensic Aspects of Addiction Psychiatry: Risk, Responsibility, and Rehabilitation (Confirmed)
-
Culpability and Criminal Responsibility in Addicted Offenders
An exploration of how substance misuse disorders impact mens rea (criminal intent), including the legal frameworks of diminished responsibility, insanity, and automatism. Case law and practical examples will be discussed to illustrate the role of expert psychiatric evidence in court.
-
Addiction, Risk, and Recidivism in Forensic Populations
A detailed examination of how addiction contributes to violence, acquisitive crime, and sexual offending in forensic settings. This section will include an overview of validated tools used to assess risk in offenders with comorbid addiction and mental illness.
-
Rehabilitation and Risk Management of Offenders with Addiction
Discussion of evidence-based treatment models (e.g. dual diagnosis pathways, trauma-informed care, and therapeutic jurisprudence) in secure settings and prisons. The presentation will also cover the medico-legal challenges of managing addiction within the forensic framework, including issues of consent, capacity, and long-term risk.
Q&A
Q&A
Networking and Lunch
Networking and Lunch
Gaming Disorder in the UK: An overview (Confirmed)
The talk will address both the clinical presentation and the work of the only NHS clinic to treat this disorder.
Developing Addiction Psychiatry Training and Workforce
Substance Use Disorders (SUD) and Co-occurring Substance Use and Mental Health Disorders (CoSUM) form a significant proportion of patients in clinical Psychiatric practice but are likely to be underidentified, leading to poorer outcomes for patients presenting with these conditions. Across the world, there is a significant short-fall in mental health professionals skilled in recognising, assessing, diagnosing and managing the care of people with SUD and CoSUM. The talk will explore the wider training and curricular issues in Addiction Psychiatry particularly focusing on solutions to improve the numbers and skill mix of mental health workforce equipped to assess and treat SUD and CoSUM.
Cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder (Confirmed)
Long-Acting Injectable Buprenorphine is a recent advance in the treatment of opioid use disorder which can be administered in weekly or monthly injections, allowing people with opioid use disorder to engage with daily activities without the need or daily supervised consumption. However, there is little research on the how and why this treatment may be beneficial compared to standard of care.
This talk discusses a study where we compared self-reported outcomes for people who are prescribed Long-Acting Injectable Buprenorphine compared to other medications for opioid use disorder. We used logistic regression to identify predictors of being prescribed LAIB compared to other medication for opioid use disorder, and we compared changes in self-reported physical health, mental health and quality of life over a one-year period. We contextualised the results with qualitative interviews with people with opioid use disorder and clinicians.
Q&A
Q&A
Psychedelic assisted treatments- what the future holds (Confirmed)
This lecture will explain the brain science of psychedelics and then show how they are being developed for the treatment of tobacco and alcohol addiction and then David Nutt will share details of the upcoming studies on opioid and gambling addictions.
End of Conference
End of Conference
3rd iPAM® Event Gallery
